NYU Langone

Running trials

• Recruiting

  NORM-HF Pivotal Study

  NCT07574593· Source

• Recruiting

  A Study to Evaluate Safety, Tolerability, and Efficacy of AB-1009 Gene Therapy (GAA Gene) in Adult Participants With Late-Onset Pompe Disease (PROGRESS-GT LOPD)

  NCT07282847· Phase 1/2· Source

• Recruiting

  A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors

  NCT07361562· Phase 1· Source

• Recruiting

  Shield Post-Approval Study Protocol

  NCT06880055· Source

• Recruiting

  XVIVO Heart Box (XHB) With Supplemented XVIVO Heart Solution (SXHS) Continued Access Protocol (CAP)

  NCT06895070· Source

• Recruiting

  Comparing Standard of Care Biopsy System to a Novel Biopsy Needle System by Computational Pathologic Analysis

  NCT06830265· Source

• Recruiting

  A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer

  NCT06533644· Phase 2· Source

• Active, not recruiting

  Evaluation of the Safety and Efficacy of Revita® DMR on Body Weight Maintenance in Subjects With Obesity Who Have Achieved at Least 15% Weight Loss on Tirzepatide

  NCT06484114· Source

• Recruiting

  Helmsley 3.0: Abbreviated MRE

  NCT06533228· Source

• Active, not recruiting

  A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)

  NCT05904886· Phase 3· Source

• Recruiting

  Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

  NCT06040541· Phase 1· Source

• Active, not recruiting

  Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

  NCT05945823· Phase 2· Source

• Active, not recruiting

  Assessment of Combined CCM and ICD Device in HFrEF

  NCT05855135· Source

• Active, not recruiting

  Electrical Stimulation for the Treatment of Glaucoma

  NCT05626491· Source

• Active, not recruiting

  Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease

  NCT05099770· Phase 3· Source

• Recruiting

  Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II

  NCT05102019· Source

• Recruiting

  First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

  NCT05216432· Phase 1· Source

• Recruiting

  A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

  NCT04913285· Phase 1· Source

• Active, not recruiting

  Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

  NCT04956640· Phase 1/2· Source

• Recruiting

  Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

  NCT04900818· Phase 1· Source

• Active, not recruiting

  Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC

  NCT03527108· Phase 2· Source

• Active, not recruiting

  Diffusion MRI for Head and Neck Cancer

  NCT04251481· Source

• Active, not recruiting

  A Registry Study of NanoKnife IRE for Stage 3 Pancreatic Cancer

  NCT03899649· Source

• Active, not recruiting

  Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)

  NCT03393884· Phase 1/2· Source

• Active, not recruiting

  Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD

  NCT03417388· Phase 4· Source

• Active, not recruiting

  A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)

  NCT03157128· Phase 1/2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer3 recruiting
• Colorectal cancer2 recruiting
• Heart failure2 recruiting
• Pancreatic cancer2 recruiting
• Coronary artery disease1 recruiting
• Crohn's disease1 recruiting
• Gastric and esophageal cancer1 recruiting
• Liver and biliary tract cancer1 recruiting
• Melanoma1 recruiting
• Metastatic breast cancer1 recruiting
• Pompe disease1 recruiting
• Prostate cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus

  NCT06362265· Phase 1· Source

• Completed

  Photobiomodulation to Demonstrate Safety and Reduce the Incidence of Oral Mucositis in Adult Head & Neck Cancer Patients

  NCT03972527· Source

• Completed

  A Study to Learn About How Well Riociguat Works, How Safe it is and How it is Used Under Real World Conditions in Patients in the United States Who Are Receiving Riociguat for High Blood Pressure in the Arteries That Carry Blood From the Heart to the Lungs (Pulmonary Arterial Hypertension, PAH)

  NCT04813926· Source

• Completed

  The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC

  NCT04338399· Phase 3· Source

• Completed

  A Study of Baricitinib in Participants With Rheumatoid Arthritis

  NCT04086745· Phase 4· Source

• Completed

  Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]

  NCT03555422· Phase 3· Source